Abstract
We reviewed clinicopathologic features and treatment outcomes in seven patients diagnosed with Stage 4/Group IV orbital sarcoma and treated on IRSG protocols I-III. Three patients had embryonal rhabdomyosarcoma (RMS), and two patients each had alveolar RMS or unclassified sarcoma. Median age at diagnosis was 1.8 years (range 0.2-6.9 years). All patients had bone marrow involvement, including six with normal complete blood count at diagnosis. Cerebrospinal fluid was normal in six patients. Three patients survived >5 years, including one with local recurrence. In conclusion, further study is needed to determine necessity of bone marrow and CSF examination in orbital sarcoma patients.
Copyright 2010 Wiley-Liss, Inc.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Child
-
Child, Preschool
-
Cisplatin / therapeutic use
-
Combined Modality Therapy
-
Dactinomycin / therapeutic use
-
Doxorubicin / therapeutic use
-
Etoposide / therapeutic use
-
Female
-
Humans
-
Male
-
Neoplasm Metastasis / drug therapy
-
Neoplasm Metastasis / pathology*
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Staging
-
Orbital Neoplasms / mortality
-
Orbital Neoplasms / pathology*
-
Orbital Neoplasms / therapy
-
Radiotherapy
-
Sarcoma / mortality
-
Sarcoma / pathology*
-
Sarcoma / therapy
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Dactinomycin
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cisplatin